These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23074283)

  • 1. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
    Eke I; Schneider L; Förster C; Zips D; Kunz-Schughart LA; Cordes N
    Cancer Res; 2013 Jan; 73(1):297-306. PubMed ID: 23074283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis.
    Eke I; Storch K; Krause M; Cordes N
    Cancer Res; 2013 Oct; 73(19):5869-79. PubMed ID: 23950208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
    Eke I; Cordes N
    Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of the EGFR/β1 integrin connecting proteins PINCH1 and Nck2 radiosensitizes three-dimensional SCC cell cultures.
    Rossow L; Eke I; Dickreuter E; Cordes N
    Oncol Rep; 2015 Jul; 34(1):469-76. PubMed ID: 26004008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
    Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
    Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
    Ohnishi Y; Yasui H; Kakudo K; Nozaki M
    Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.
    Skvortsova I; Skvortsov S; Raju U; Stasyk T; Riesterer O; Schottdorf EM; Popper BA; Schiestl B; Eichberger P; Debbage P; Neher A; Bonn GK; Huber LA; Milas L; Lukas P
    Radiother Oncol; 2010 Jul; 96(1):108-15. PubMed ID: 20451273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
    Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
    Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of EGFR antagonists gefitinib (Iressa) and C225 (Cetuximab) on MnSOD-plasmid liposome transgene radiosensitization of a murine squamous cell carcinoma cell line.
    Epperly MW; Franicola D; Zhang X; Nie S; Greenberger JS
    In Vivo; 2006; 20(6B):791-6. PubMed ID: 17203769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation-induced dimer formation of EGFR: implications for the radiosensitizing effect of cetuximab.
    Kiyozuka M; Akimoto T; Fukutome M; Motegi A; Mitsuhashi N
    Anticancer Res; 2013 Oct; 33(10):4337-46. PubMed ID: 24123001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
    Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
    Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM; Saigal B; Donato NJ
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Wong TW; Kramer RA; Wild R; Lee FY
    Clin Cancer Res; 2005 Aug; 11(15):5558-65. PubMed ID: 16061873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.